← Evidence map

ArticleThe Lancet regional health. Europe2024

Correction to "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination" [The Lancet Regional Health - Europe 38 (2024) 100829].

David Hodgson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Correction to "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination" [The Lancet Regional Health - Europe 38 (2024) 100829]. | OpenQuestion